{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:49:37Z","timestamp":1770972577741,"version":"3.50.1"},"reference-count":73,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Cardiovascular Disease"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> Management of high blood pressure (BP) typically requires adherence to medication regimes. However, it is known that the COVID-19 pandemic both interrupted access to some routine prescriptions and changed some patient health behaviours. <\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p> This study, therefore, retrospectively investigated prescription reimbursement of cardiovascular (CVD) medicines as a proxy measure for patient adherence and access to medicines during the pandemic. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> A cohort study of all primary care patients in England prescribed CVD medicines. The exposure was to the global pandemic. Prescriptions were compared before and after the pandemic\u2019s onset. Statistical variation was the outcome of interest. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> Descriptive statistics show changes to monthly prescriptions, with wide confidence intervals indicating varying underlying practice. Analysis of variance reveals statistically significant differences for bendroflumethiazide, potassium-sparing diuretics, nicorandil, ezetimibe, ivabradine, ranolazine, colesevelam and midodrine. After the pandemic began (March\u2013October 2020), negative parameters are observed for ACE inhibitors, beta-blockers, calcium channel blockers, statins, antiplatelet, antithrombotics, ARBs, loop diuretics, doxazosin, bendroflumethiazide, nitrates and indapamide, indicating decelerating monthly prescription items (statistically significant declines of calcium channel blockers, antithrombotic, adrenoreceptor blockers and diuretics) of CVD medicines within the general population. Many data points are not statistically significant, but fluctuations remain clinically important for the large population of patients taking these medications. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p> A concerning decline in uptake of CVD therapies for chronic heart disease was observed. Accessible screening and treatment alongside financial relief on prescription levies are needed. A video abstract is (4 min 51 s) available: https:\/\/bit.ly\/39gvEHi <\/jats:p><\/jats:sec>","DOI":"10.1177\/17539447221137170","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T15:33:52Z","timestamp":1669304032000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England\u2019s prescription data during the COVID-19 pandemic (January 2019 to October 2020)"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0004-2131","authenticated-orcid":false,"given":"Ravina","family":"Barrett","sequence":"first","affiliation":[{"name":"School of Applied Sciences, University of Brighton, Cockcroft Building, Lewes Road, Moulsecoomb, Brighton BN2 4GJ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Hodgkinson","sequence":"additional","affiliation":[{"name":"Murray Learning Centre, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"bibr1-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.14240"},{"key":"bibr2-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2016_99"},{"key":"bibr3-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-309573"},{"key":"bibr4-17539447221137170","volume":"140","author":"Arnett DK","year":"2019","journal-title":"Circulation"},{"key":"bibr5-17539447221137170","volume":"126","author":"Fihn SD","year":"2012","journal-title":"Circulation"},{"key":"bibr6-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr400"},{"key":"bibr7-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311849"},{"key":"bibr8-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61215-4"},{"key":"bibr9-17539447221137170","unstructured":"World Health Organization. WHO model lists of essential medicines, https:\/\/www.who.int\/groups\/expert-committee-on-selection-and-use-of-essential-medicines\/essential-medicines-lists (accessed 9 October 2021)."},{"key":"bibr10-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23384"},{"key":"bibr11-17539447221137170","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173982"},{"key":"bibr12-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"bibr13-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7"},{"key":"bibr14-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2020.198146"},{"key":"bibr15-17539447221137170","doi-asserted-by":"publisher","DOI":"10.7150\/thno.48076"},{"key":"bibr16-17539447221137170","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112343"},{"key":"bibr17-17539447221137170","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.639177"},{"key":"bibr18-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.02.010"},{"key":"bibr19-17539447221137170","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18168567"},{"key":"bibr20-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1016\/j.ancard.2021.01.006"},{"key":"bibr21-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1002\/bco2.101"},{"key":"bibr22-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1007\/s40199-021-00431-7"},{"key":"bibr23-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2022.1985470"},{"key":"bibr24-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2078100"},{"key":"bibr25-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2264"},{"key":"bibr26-17539447221137170","volume":"12","author":"Bordes SJ","year":"2020","journal-title":"Cureus"},{"key":"bibr27-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-020-00451-x"},{"key":"bibr28-17539447221137170","unstructured":"Blood Pressure UK. Covid-19 advice for people with high blood pressure, https:\/\/www.bloodpressureuk.org\/news\/news\/covid-19-advice-for-people-with-high-blood-pressure-html (accessed 6 April 2022)."},{"key":"bibr29-17539447221137170","unstructured":"British Medical Association. NHS backlog data analysis. The British Medical Association is the trade union and professional body for doctors in the UK, https:\/\/www.bma.org.uk\/advice-and-support\/nhs-delivery-and-workforce\/pressures\/nhs-backlog-data-analysis (accessed 20 May 2022)."},{"key":"bibr30-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o51"},{"key":"bibr31-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-021-01496-8"},{"key":"bibr32-17539447221137170","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2020.1112"},{"key":"bibr33-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2775"},{"key":"bibr34-17539447221137170","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.685696"},{"key":"bibr35-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2021.10.009"},{"key":"bibr36-17539447221137170","unstructured":"English Prescribing Dataset (EPD)\u2013Open Data Portal BETA, https:\/\/opendata.nhsbsa.net\/dataset\/english-prescribing-data-epd (accessed 25 April 2020)."},{"key":"bibr37-17539447221137170","unstructured":"Office for National Statistics. Vital statistics in the UK: births, deaths and marriages, https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/vitalstatisticspopulationandhealthreferencetables (2021, accessed 19 March 2021)."},{"key":"bibr38-17539447221137170","unstructured":"Office for National Statistics. Deaths registered monthly in England and Wales \u2013 Office for National Statistics, https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/datasets\/monthlyfiguresondeathsregisteredbyareaofusualresidence (accessed 19 March 2021)."},{"key":"bibr39-17539447221137170","unstructured":"Office for National Statistics. Provisional births in England and Wales, https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/livebirths\/datasets\/provisionalbirthsinenglandandwales (accessed 19 March 2021)."},{"key":"bibr40-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30415-X"},{"key":"bibr41-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30447-1"},{"key":"bibr42-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885"},{"key":"bibr43-17539447221137170","unstructured":"Cochrane Effective Practice Organisation of Care (EPOC). Interrupted time series (ITS) analyses. EPOC resources for review authors, 2017, https:\/\/docplayer.net\/11490296-Interrupted-time-series-its-analyses.html"},{"key":"bibr44-17539447221137170","first-page":"348","volume":"46","author":"Lopez Bernal J","year":"2016","journal-title":"Int J Epidemiol"},{"key":"bibr45-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2750"},{"key":"bibr46-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyab216"},{"key":"bibr47-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1177\/1077558720971117"},{"key":"bibr48-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01235-8"},{"key":"bibr49-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1177\/096228029600500102"},{"key":"bibr50-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1177\/003754979105700508"},{"key":"bibr51-17539447221137170","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahl\u00f6f B","year":"2005","journal-title":"Lancet Lond Engl"},{"key":"bibr52-17539447221137170","unstructured":"Office for National Statistics. Total deaths in the UK in 2020 and deaths from heart attacks, heart disease, cancer, and Alzheimer\u2019s and dementia,2016 to 2020\u2013Office for National Statistics, https:\/\/www.ons.gov.uk\/aboutus\/transparencyandgovernance\/freedomofinformationfoi\/totaldeathsintheukin2020anddeathsfromheartattacksheartdiseasecancerandalzheimersanddementia2016to2020 (2021, accessed 23 May 2022)."},{"key":"bibr53-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.10.055"},{"key":"bibr54-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105759"},{"key":"bibr55-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-021-07154-0"},{"key":"bibr56-17539447221137170","doi-asserted-by":"publisher","DOI":"10.2196\/23311"},{"key":"bibr57-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2020.09.015"},{"key":"bibr58-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01368-6"},{"key":"bibr59-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001784"},{"key":"bibr60-17539447221137170","unstructured":"Williams H. Guidance for the safe switching of warfarin to direct oral anticoagulants (DOACs) for patients with non-valvular AF and venous thromboembolism (DVT \/ PE) during the coronavirus pandemic, https:\/\/www.rpharms.com\/Portals\/0\/RPS%20document%20library\/Open%20access\/Coronavirus\/FINAL%20Guidance%20on%20safe%20switching%20of%20warfarin%20to%20DOAC%20COVID-19%20Mar%202020.pdf?ver=2020-03-26-180945-627 (2020, accessed 11 October 2021.)"},{"key":"bibr61-17539447221137170","unstructured":"NHS, England NHS and Improvement. Clinical guide for the management of anticoagulant services during the coronavirus pandemic, 2020, https:\/\/www.nice.org.uk\/media\/default\/about\/covid-19\/specialty-guides\/specialty-guide-anticoagulant-services-and-coronavirus.pdf"},{"key":"bibr62-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-021-00918-7"},{"key":"bibr63-17539447221137170","unstructured":"NHS and England. Cardiovascular disease (CVD), https:\/\/www.england.nhs.uk\/ourwork\/clinical-policy\/cvd\/ (accessed 11 October 2021)."},{"key":"bibr64-17539447221137170","unstructured":"National Health Service. The NHS Long Term Plan, https:\/\/www.longtermplan.nhs.uk\/wp-content\/uploads\/2019\/08\/nhs-long-term-plan-version-1.2.pdf (2019, accessed 11 October 2021)."},{"key":"bibr65-17539447221137170","unstructured":"National Health Service. What is an NHS health check? https:\/\/www.nhs.uk\/conditions\/nhs-health-check\/what-is-an-nhs-health-check-new\/ (2019, accessed 11 October 2021)."},{"key":"bibr66-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30309-X"},{"key":"bibr67-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61184-7"},{"key":"bibr68-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320981174"},{"key":"bibr69-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(20)30201-2"},{"key":"bibr70-17539447221137170","unstructured":"Office for National Statistics. Indicator 3.8.2 \u2013 proportion of population with large household expenditures on health as a share of total household expenditure or income \u2013 U.K. Indicators for the Sustainable Development Goals, https:\/\/sdgdata.gov.uk\/3-8-2\/ (2022, accessed 20 May 2022)."},{"key":"bibr71-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.01.033"},{"key":"bibr72-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0000000000001367"},{"key":"bibr73-17539447221137170","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.11.021"}],"container-title":["Therapeutic Advances in Cardiovascular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17539447221137170","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17539447221137170","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17539447221137170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T15:01:39Z","timestamp":1740927699000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17539447221137170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":73,"alternative-id":["10.1177\/17539447221137170"],"URL":"https:\/\/doi.org\/10.1177\/17539447221137170","relation":{},"ISSN":["1753-9447","1753-9455"],"issn-type":[{"value":"1753-9447","type":"print"},{"value":"1753-9455","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"17539447221137170"}}